Brokers Set Expectations for Krystal Biotech FY2025 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Krystal Biotech in a report issued on Thursday, February 20th. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings per share of $6.22 for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $215.00 target price on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. The company had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm’s revenue for the quarter was up 116.4% on a year-over-year basis. During the same quarter last year, the business posted $0.30 EPS.

Several other research analysts also recently commented on KRYS. Citigroup raised their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, February 20th. Chardan Capital raised their price target on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. Finally, HC Wainwright restated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a report on Wednesday, February 19th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $210.00.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS opened at $181.10 on Monday. The firm has a market cap of $5.22 billion, a PE ratio of 60.57 and a beta of 0.84. The firm’s 50 day simple moving average is $158.24 and its 200-day simple moving average is $175.31. Krystal Biotech has a one year low of $125.85 and a one year high of $219.34.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares in the company, valued at $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 14.10% of the company’s stock.

Institutional Trading of Krystal Biotech

Several hedge funds have recently modified their holdings of the company. Norges Bank bought a new position in shares of Krystal Biotech during the 4th quarter worth approximately $34,391,000. Soleus Capital Management L.P. grew its holdings in Krystal Biotech by 65.2% in the fourth quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company’s stock worth $56,144,000 after purchasing an additional 141,400 shares during the last quarter. Segall Bryant & Hamill LLC increased its position in shares of Krystal Biotech by 352.4% during the third quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock worth $28,605,000 after purchasing an additional 122,407 shares in the last quarter. State Street Corp lifted its holdings in shares of Krystal Biotech by 9.0% during the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after purchasing an additional 119,936 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Krystal Biotech in the 4th quarter worth $15,989,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).